Latest news and press releases about Dermata Therapeutics, Inc. (DRMA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Price
| Price | $1.15 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.30 |
| EV / EBITDA | 0.42 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -166.67% |
| Return on Invested Capital | -246.61% |
| Return on Assets | -157.28% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ARTL · ATXI · CARM · ELAB · GTBP · LIPO · PBM
Explore sector: Healthcare · Biotechnology
More sections of DRMA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks